Overview
The theme of the TRIAD program is the development of a process by which broad-spectrum vaccines can be 1) engineered with the help of immunoinformatics tools and 2) tested using validated in vitro and in vivo methods. The in vitro / in vivo evaluation is supported by the “cell mediated immunity” or TRIAD CMI scientific core. The CMI Core was designed to “Create” the capabilities that are required for accelerated vaccine design, i.e., the equipment, staffing, and capabilities required to support these epitope verification processes and analyses. All research and technology development projects within the program specify that some or all of the resources provided by this core will be used by each project. The capabilities and infrastructure provided by the core to date include the following:
1) Flow cytometric and cytokine bead analysis (Cellular phenotyping and cytokine profiling)
2) ELISpot assay analysis (Lower cost initial screening assay for “first pass” screening)
3) Human leukocyte cryopreservation and short term storage (for “reference material”)
4) HLA transgenic mouse colony management (for in vivo validation prior to IND filing)
